After Reaching All-Time Low, Is Aequus Pharmaceuticals Inc’s Near-Term Analysis Positive?


The stock of Aequus Pharmaceuticals Inc (CVE:AQS) reached all time low today, Sep, 13 and still has $0.25 target or 14.00% below today’s $0.29 share price. This indicates more downside for the $12.56M company. This technical setup was reported by If the $0.25 PT is reached, the company will be worth $1.76 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 67,500 shares traded hands or 184.93% up from the average. Aequus Pharmaceuticals Inc (CVE:AQS) has risen 6.00% since August 14, 2016 and is uptrending. It has underperformed by 10.49% the S&P500.

Aequus Pharmaceuticals Inc. is a specialty pharmaceutical firm focused on developing and commercializing products. The company has a market cap of $12.56 million. The Firm operates through the segment of sales and marketing of pharmaceutical drugs developed by the Company or by its collaborative partners. It currently has negative earnings. The Company’s products include tacrolimus immediate releaser, which is an immunosuppressive therapy used for the treatment and prevention of acute rejection following organ transplantation; Vistitan, which is a ophthalmology product; Topiramate extended-release , which is a once-daily topiramate product designed for patient compliance, and Oxcarbazepine XR, which is a once-daily oxcarbazepine product.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply